

PB 41 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 April 2021

**THEA CONNOLLY**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1 Name

2 Commencement 1

3 Authority 1

4 Schedule 1

Schedule 1—Amendments 2

National Health (Continued Dispensing - Emergency Measures) Determination 2020 2

1 Name

1. This instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4)*.
2. This instrument may also be cited as PB 41 of 2021.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 May 2021.* |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

**3 Authority**

This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

1. Schedule 1, entry for Aciclovir
2. insert as first entry:

|  |  |  |
| --- | --- | --- |
|  | Eye ointment 30 mg per g, 4.5 g | Application to the eye |

1. omit:

|  |  |  |
| --- | --- | --- |
|  | Eye ointment 30 mg per g, 4.5 g (Acivision) | Application to the eye |

1. Schedule 1, after entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg

*insert:*

|  |  |  |
| --- | --- | --- |
| Cannabidiol | Oral liquid 100 mg per mL, 100 mL | Oral |

1. Schedule 1, entry for Mesalazine

*substitute:*

|  |  |  |
| --- | --- | --- |
| Mesalazine | Enemas 1 g in 100 mL, 7 | Rectal |
|  | Enemas 2 g in 60 mL, 7 | Rectal |
|  | Enemas 4 g in 60 mL, 7 | Rectal |
|  | Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | Rectal |
|  | Sachet containing granules, 500 mg per sachet | Oral |
|  | Sachet containing granules, 1 g per sachet | Oral |
|  | Sachet containing granules, 1.5 g per sachet | Oral |
|  | Sachet containing granules, 3 g per sachet | Oral |
|  | Sachet containing prolonged release granules, 1 g per sachet | Oral |
|  | Sachet containing prolonged release granules, 2 g per sachet | Oral |
|  | Sachet containing prolonged release granules, 4 g per sachet | Oral |
|  | Suppository 1 g | Rectal |
|  | Suppository (moulded) 1 g | Rectal |
|  | Tablet 250 mg (enteric coated) | Oral |
|  | Tablet 500 mg (enteric coated) | Oral |
|  | Tablet 500 mg (prolonged release) | Oral |
|  | Tablet 800 mg (enteric coated) | Oral |
|  | Tablet 1 g (enteric coated) | Oral |
|  | Tablet 1 g (prolonged release) | Oral |
|  | Tablet 1.2 g (prolonged release) | Oral |
|  | Tablet 1.6 g (enteric coated) | Oral |

1. Schedule 1, entry for Norethisterone with ethinylestradiol

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets USP | Oral |